12,372 trials
Colorectal Cancer
Primary: Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) — 11.86; 11.93 Months — p=0.3022
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Asthma
Primary: Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22…
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC Pain Score at 26 Weeks (ITT Population) — -46.4; -46.6; -45.0 units on a scale — p=0.5874
Breast Ductal Carcinoma In Situ
Primary: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival — 95.1; 96.1 percentage of patients event free
Schizophrenia
Primary: PANSS Total Score Mean Change From Baseline to Endpoint — -22.9; -11.0; -0.8; -18.9 units on a scale
Glaucoma · Open-Angle Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 24.45; 24.38 millimeters of mercury (mmHg)
Edematous Fibrosclerotic Panniculopathy (EFP) · Cellulite
Primary: The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh — 58 Participants
Episodic Migraine
Primary: Percentage of Participants With at Least 50% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment) — 30.3; 13.7 Percentage…
Infection, Human Immunodeficiency Virus · HIV Infections · Arthralgia
Primary: Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir — 55.045; 42.473; 78.917 Micrograms*hours per…
Peritoneal Cancer
Primary: Efficacy of TEA vs 4Q-TAP in QoR at Postoperative Day (POD)2 — -45; -50 score on a scale
Infertility, Female
Primary: the Number of M2 Oocytes Retrieved — 6; 4.5 oocytes — p=0.254
Phenylketonuria (PKU)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 — 36; 17; 7; 1 Participants
Bleeding
Primary: Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor — -93.3; -94.1; -71.3; -75.41 Percent Change
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Intraocular Pressure — 20.35; 20.79; 17.38; 18.31 mmHg — p=0.0006